In patients with gastrinomas located in the pancreas (approximately 25% of patients) and MEN1, the role of surgery remains debated, and a risk-benefit assessment should always be evaluated [2, 21, 22]. This evidence concerns the gene MEN1 and gastrin-producing neuroendocrine tumor.